Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
Identifieur interne : 003277 ( Main/Exploration ); précédent : 003276; suivant : 003278Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
Auteurs : Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada, États-Unis] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-11.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Amantadine (therapeutic use), Animal model, Animals, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Apomorphine (adverse effects), Behavior, Behavior, Animal (drug effects), Behavior, Animal (physiology), Callithrix, Disability Evaluation, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Interactions, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), Dyskinesia, Drug-Induced (physiopathology), Female, Grooming (drug effects), Grooming (physiology), Hallucinations (drug therapy), Hallucinations (etiology), Levodopa (adverse effects), MPTP‐lesioned primate, Nervous system diseases, Parkinson disease, Parkinson's disease, Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (physiopathology), Primates, Psychomotor Agitation (drug therapy), Psychomotor Agitation (etiology), Psychosis, Psychotic Disorders (drug therapy), Psychotic Disorders (etiology), Psychotic Disorders (physiopathology), Statistics, Nonparametric, Stereotyped Behavior (drug effects), Stereotyped Behavior (physiology), animal model, psychosis.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Apomorphine, Levodopa.
- chemical , therapeutic use : Amantadine, Antiparkinson Agents.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemically induced : Parkinsonian Disorders.
- drug effects : Behavior, Animal, Grooming, Stereotyped Behavior.
- drug therapy : Dyskinesia, Drug-Induced, Hallucinations, Parkinsonian Disorders, Psychomotor Agitation, Psychotic Disorders.
- etiology : Dyskinesia, Drug-Induced, Hallucinations, Psychomotor Agitation, Psychotic Disorders.
- physiology : Behavior, Animal, Grooming, Stereotyped Behavior.
- physiopathology : Dyskinesia, Drug-Induced, Parkinsonian Disorders, Psychotic Disorders.
- Animals, Callithrix, Disability Evaluation, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Interactions, Female, Statistics, Nonparametric.
Abstract
Investigation of the pathophysiology of psychosis in Parkinson's disease (PD), as well as the assessment of potential novel therapeutics, has been limited by the lack of a well‐validated animal model. MPTP‐lesioned primates exhibit abnormal behaviors that are distinct from dyskinesia and parkinsonism and may represent behavioral correlates of neural processes related to psychosis in PD. Here we assess four types of behavior—agitation, hallucinatory‐like responses to nonapparent stimuli, obsessive grooming, and stereotypies that are termed “psychosis‐like”—and define their pharmacology using a psychosis‐like behavior rating scale. By assessing the actions of drugs known to enhance or attenuate psychosis in PD patients, we find that the pharmacology of these behaviors recapitulates, in several respects, the pharmacology of psychosis in PD. Thus, levodopa and apomorphine elicited psychosis‐like behaviors. Amantadine significantly decreased levodopa‐induced dyskinesia but exacerbated psychosis‐like behaviors. Haloperidol reduced psychosis‐like behaviors but at the expense of increased parkinsonian disability while the atypical neuroleptics clozapine and quetiapine reduced psychosis‐like behaviors without significant effect on parkinsonian disability. The response of different components of the psychotomimetic behavior suggested the involvement of both dopaminergic and nondopaminergic mechanisms in their expression. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21073
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000779
- to stream Istex, to step Curation: 000779
- to stream Istex, to step Checkpoint: 001D36
- to stream PubMed, to step Corpus: 002B08
- to stream PubMed, to step Curation: 002B08
- to stream PubMed, to step Checkpoint: 002B70
- to stream Ncbi, to step Merge: 001831
- to stream Ncbi, to step Curation: 001831
- to stream Ncbi, to step Checkpoint: 001831
- to stream Main, to step Merge: 004590
- to stream PascalFrancis, to step Corpus: 001917
- to stream PascalFrancis, to step Curation: 001404
- to stream PascalFrancis, to step Checkpoint: 001966
- to stream Main, to step Merge: 004A61
- to stream Main, to step Curation: 003277
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title>
<author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name>
</author>
<author><name sortKey="Gomez Amirez, Jordi" sort="Gomez Amirez, Jordi" uniqKey="Gomez Amirez J" first="Jordi" last="Gomez-Ramirez">Jordi Gomez-Ramirez</name>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
</author>
<author><name sortKey="Pires, Donna" sort="Pires, Donna" uniqKey="Pires D" first="Donna" last="Pires">Donna Pires</name>
</author>
<author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D66C7CD0F71954996563291D61D0CDCC2B400A5F</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21073</idno>
<idno type="url">https://api.istex.fr/document/D66C7CD0F71954996563291D61D0CDCC2B400A5F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000779</idno>
<idno type="wicri:Area/Istex/Curation">000779</idno>
<idno type="wicri:Area/Istex/Checkpoint">001D36</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Visanji N:pharmacological:characterization:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16960862</idno>
<idno type="wicri:Area/PubMed/Corpus">002B08</idno>
<idno type="wicri:Area/PubMed/Curation">002B08</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002B70</idno>
<idno type="wicri:Area/Ncbi/Merge">001831</idno>
<idno type="wicri:Area/Ncbi/Curation">001831</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001831</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Visanji N:pharmacological:characterization:of</idno>
<idno type="wicri:Area/Main/Merge">004590</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:07-0021714</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001917</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001404</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001966</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Visanji N:pharmacological:characterization:of</idno>
<idno type="wicri:Area/Main/Merge">004A61</idno>
<idno type="wicri:Area/Main/Curation">003277</idno>
<idno type="wicri:Area/Main/Exploration">003277</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title>
<author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gomez Amirez, Jordi" sort="Gomez Amirez, Jordi" uniqKey="Gomez Amirez J" first="Jordi" last="Gomez-Ramirez">Jordi Gomez-Ramirez</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pires, Donna" sort="Pires, Donna" uniqKey="Pires D" first="Donna" last="Pires">Donna Pires</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry, Toronto Western Hospital, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Current Address: Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-11">2006-11</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1879">1879</biblScope>
<biblScope unit="page" to="1891">1891</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D66C7CD0F71954996563291D61D0CDCC2B400A5F</idno>
<idno type="DOI">10.1002/mds.21073</idno>
<idno type="ArticleID">MDS21073</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>Amantadine (therapeutic use)</term>
<term>Animal model</term>
<term>Animals</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Apomorphine (adverse effects)</term>
<term>Behavior</term>
<term>Behavior, Animal (drug effects)</term>
<term>Behavior, Animal (physiology)</term>
<term>Callithrix</term>
<term>Disability Evaluation</term>
<term>Disease Models, Animal</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Interactions</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Dyskinesia, Drug-Induced (physiopathology)</term>
<term>Female</term>
<term>Grooming (drug effects)</term>
<term>Grooming (physiology)</term>
<term>Hallucinations (drug therapy)</term>
<term>Hallucinations (etiology)</term>
<term>Levodopa (adverse effects)</term>
<term>MPTP‐lesioned primate</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Parkinsonian Disorders (chemically induced)</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Parkinsonian Disorders (physiopathology)</term>
<term>Primates</term>
<term>Psychomotor Agitation (drug therapy)</term>
<term>Psychomotor Agitation (etiology)</term>
<term>Psychosis</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Psychotic Disorders (etiology)</term>
<term>Psychotic Disorders (physiopathology)</term>
<term>Statistics, Nonparametric</term>
<term>Stereotyped Behavior (drug effects)</term>
<term>Stereotyped Behavior (physiology)</term>
<term>animal model</term>
<term>psychosis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Apomorphine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term>
<term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term>
<term>Grooming</term>
<term>Stereotyped Behavior</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Hallucinations</term>
<term>Parkinsonian Disorders</term>
<term>Psychomotor Agitation</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Hallucinations</term>
<term>Psychomotor Agitation</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Behavior, Animal</term>
<term>Grooming</term>
<term>Stereotyped Behavior</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinsonian Disorders</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Callithrix</term>
<term>Disability Evaluation</term>
<term>Disease Models, Animal</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Interactions</term>
<term>Female</term>
<term>Statistics, Nonparametric</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Comportement</term>
<term>Modèle animal</term>
<term>Parkinson maladie</term>
<term>Primates</term>
<term>Psychose</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Investigation of the pathophysiology of psychosis in Parkinson's disease (PD), as well as the assessment of potential novel therapeutics, has been limited by the lack of a well‐validated animal model. MPTP‐lesioned primates exhibit abnormal behaviors that are distinct from dyskinesia and parkinsonism and may represent behavioral correlates of neural processes related to psychosis in PD. Here we assess four types of behavior—agitation, hallucinatory‐like responses to nonapparent stimuli, obsessive grooming, and stereotypies that are termed “psychosis‐like”—and define their pharmacology using a psychosis‐like behavior rating scale. By assessing the actions of drugs known to enhance or attenuate psychosis in PD patients, we find that the pharmacology of these behaviors recapitulates, in several respects, the pharmacology of psychosis in PD. Thus, levodopa and apomorphine elicited psychosis‐like behaviors. Amantadine significantly decreased levodopa‐induced dyskinesia but exacerbated psychosis‐like behaviors. Haloperidol reduced psychosis‐like behaviors but at the expense of increased parkinsonian disability while the atypical neuroleptics clozapine and quetiapine reduced psychosis‐like behaviors without significant effect on parkinsonian disability. The response of different components of the psychotomimetic behavior suggested the involvement of both dopaminergic and nondopaminergic mechanisms in their expression. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Maryland</li>
<li>Ontario</li>
</region>
<settlement><li>Toronto</li>
</settlement>
<orgName><li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name>
</noRegion>
<name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<name sortKey="Gomez Amirez, Jordi" sort="Gomez Amirez, Jordi" uniqKey="Gomez Amirez J" first="Jordi" last="Gomez-Ramirez">Jordi Gomez-Ramirez</name>
<name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<name sortKey="Pires, Donna" sort="Pires, Donna" uniqKey="Pires D" first="Donna" last="Pires">Donna Pires</name>
<name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name>
</country>
<country name="États-Unis"><region name="Maryland"><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003277 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003277 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:D66C7CD0F71954996563291D61D0CDCC2B400A5F |texte= Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |